PCN15 Dance as Physiotherapy in the Rehabilitation of Women Suffering from Tumour

Abstract

transformation to accelerated phase or blast crisis and death. A 5-year time horizon was considered. Each 3 months the patient faces a probability of staying in the same health state or moving to a next state. Transition to death is possible from all health states. This model was populated with efficacy data from clinical trials and different times to events were modeled using Weibull regression techniques. RESULTS: The Weibull model for the time to response and time to transformation to accelerated phase and blast crisis showed significant differences between treatment groups. The model coefficient indicated that the chance of response was higher in dasatinib patients with a difference of 12.54% versus imatinib. Patients receiving imatinib had 1.57% higher chance of moving to the accelerated phase and blast crisis earlier. Time to death did not differ significantly between treatments. CONCLUSIONS: The analysis showed earlier responses and a lower chance of reaching the accelerated phase and blast crisis faster with dasatinib 100 mg/day over imatinib 400 mg/day. Results were obtained according to the assumptions used but will need to be validated by future patient level data.